Patent & IP news for November 13, 2015

Managing the Business Lunch or Dinner—Just in Time for the Holidays from dunlapcodding.com

Linda Hazelton

A simple social outing seems like a no brainer, but there's a big difference between a well thought out occasion and a "random act of lunch."  One of the first things to ...

Share via E–mail | Twitter | Facebook

Break on Through: World IP Report 2015 from ipkitten.blogspot.com

The week of WIPO love continues.  This time it's the World Intellectual Property Report 2015, launched yesterday. Published every two years, the report looks at trends and interesting topics in IP (2013 on brands ...

Share via E–mail | Twitter | Facebook

Friday fantasies from ipkitten.blogspot.com

A message for all scammersWhat a relief!  On Tuesday, in “Swedish-Seychelles scammer stuffed -- but has he really triumphed?”, this Kat posted news of the UK Intellectual Property Office’s triumph in court against a ...

Share via E–mail | Twitter | Facebook

The Reprobel decision: fair compensation justified by actual harm (so is it OK to have a levy-free private copying exception?) from ipkitten.blogspot.com

Yesterday Jeremy reported on the latest addition to the (abundant) case law of the Court of Justice of the European Union (CJEU) on Article 5(2) of the InfoSoc Directive. This was Case C‑572 ...

Share via E–mail | Twitter | Facebook

By Kevin E. Noonan -- The Federal Circuit affirmed a judgment of invalidity based on obviousness in a decision rendered in Prometheus v Roxane. In doing so, the Court might also have given an indication of the types of claims for "personalized medicine" (in the form of methods for determining treatment of subsets of individuals suffering from a particular disease) that it would consider patentable (from one of the least patent friendly judges on the Court). The case involved ANDA litigation over alosetron, marketed by Prometheus as Lotronex®; this drug is used for treating irritable bowel syndrome (IBS). The patent-in-suit... from www.patentdocs.org

By Kevin E. Noonan -- The Federal Circuit affirmed a judgment of invalidity based on obviousness in a decision rendered in Prometheus v Roxane. In doing so, the Court might also have given an indication of ...

Share via E–mail | Twitter | Facebook

Multi-Player Gaming Patent Not Invalid Under 35 U.S.C. § 101 from docketreport.blogspot.com

The court denied defendant's motion to dismiss the asserted claims of plaintiff’s multi-player gaming patent for unpatentable subject matter and found that defendant failed to establish that the claims were directed toward an ...

Share via E–mail | Twitter | Facebook

Personalized Medicine May be Patentable, but Not for Prometheus from patentlyo.com

By Dennis Crouch Prometheus Labs v. Roxane Labs (Fed. Cir. 2015) In this case, the Federal Circuit has affirmed the district court’s holding that that Prometheus’ asserted patent claims are invalid as obvious. The ...

Share via E–mail | Twitter | Facebook

Re-hearing en banc granted to The Medicines Company in Hospira case from ipbiz.blogspot.com



As to The Medicines Company v. Hospira


Plaintiff-Appellant The Medicines Company filed a
combined petition for panel rehearing and rehearing en
banc. The petition was considered by the panel that
heard the appeal and thereafter ...

Share via E–mail | Twitter | Facebook

CAFC addresses negative claim limitations in Inphi v. Netlist from ipbiz.blogspot.com



The CAFC noted


Substantial evidence supports a finding that the specification
satisfies the written description requirement
when “the essence of the original disclosure” conveys the
necessary information—“regardless of how it” conveys
such information, and ...

Share via E–mail | Twitter | Facebook

Graphene in the news from ipbiz.blogspot.com

Phys.org notes:


The US Patent Office has recently published the patent application (no. US 2015/0301039), which was filed by the MIPT in May this year and is titled "Biological Sensor and a Method ...

Share via E–mail | Twitter | Facebook

En Banc: Should there be a Supplier Exception to the On Sale Bar? from patentlyo.com

The Federal Circuit has granted a petition for en banc rehearing in The Medicines Co. v. Hospira and requested briefing on the following questions: (a) Do the circumstances presented here constitute a commercial sale under ...

Share via E–mail | Twitter | Facebook